Most Shorted Stocks
SVRA is part of our most shorted stocks screen list, indicating it has a high short interest.
SAVARA INC (SVRA) Stock Price & Overview
NASDAQ:SVRA • US8051111016
Current stock price
5.12 USD
+0.18 (+3.64%)
At close:
5.12 USD
0 (0%)
After Hours:
The current stock price of SVRA is 5.12 USD. Today SVRA is up by 3.64%. In the past month the price decreased by -2.48%. In the past year, price increased by 61.01%.
SVRA Key Statistics
52-Week Range1.89 - 7.005
Current SVRA stock price positioned within its 52-week range.
1-Month Range4.85 - 6.24
Current SVRA stock price positioned within its 1-month range.
- Market Cap
- 1.048B
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -0.53
- Dividend Yield
- N/A
SVRA Stock Performance
Today
+3.64%
1 Week
-11.42%
1 Month
-2.48%
3 Months
-14.95%
Longer-term
6 Months +17.43%
1 Year +61.01%
2 Years +11.79%
3 Years +172.34%
5 Years +169.47%
10 Years N/A
SVRA Stock Chart
SVRA Stock Screens
SVRA currently appears in the following ChartMill screener lists.
SVRA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SVRA. When comparing the yearly performance of all stocks, SVRA is one of the better performing stocks in the market, outperforming 78.39% of all stocks.
Chartmill TA Rating
Chartmill Setup Rating
SVRA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to SVRA. The financial health of SVRA is average, but there are quite some concerns on its profitability.
Chartmill FA Analysis
Valuation
Growth
Profitability
Health
Dividend
SVRA Earnings
Next Earnings DateMay 7, 2026
Last Earnings DateMar 13, 2026
PeriodQ4 / 2025
EPS Reported-$0.13
Revenue Reported
EPS Surprise -8.12%
Revenue Surprise %
SVRA Forecast & Estimates
14 analysts have analysed SVRA and the average price target is 11.03 USD. This implies a price increase of 115.41% is expected in the next year compared to the current price of 5.12.
Analysts
Analysts85.71
Price Target11.03 (115.43%)
EPS Next Y10.58%
Revenue Next YearN/A
SVRA Groups
Sector & Classification
SVRA Financial Highlights
Over the last trailing twelve months SVRA reported a non-GAAP Earnings per Share(EPS) of -0.53. The EPS decreased by -12.77% compared to the year before.
Income Statements
Revenue(TTM)N/A
Net Income(TTM)-118.84M
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -46.89% | ||
| ROE | -58.5% | ||
| Debt/Equity | 0.15 |
Chartmill High Growth Momentum
EPS Q2Q%0%
Sales Q2Q%N/A
EPS 1Y (TTM)-12.77%
Revenue 1Y (TTM)N/A
SVRA Ownership
Ownership
Inst Owners92.03%
Shares204.66M
Float187.78M
Ins Owners2.26%
Short Float %14.61%
Short Ratio16.34
SVRA Competitors/Peers
The largest stocks on the US markets in the "Biotechnology" sub-industry
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 13.4 | 355.432B | ||
| AMGN | AMGEN INC | 15.09 | 188.147B | ||
| GILD | GILEAD SCIENCES INC | 14.75 | 165.877B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.09 | 110.672B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.03 | 80.984B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 44.76 | 41.869B | ||
| INSM | INSMED INC | N/A | 31.046B | ||
| NTRA | NATERA INC | N/A | 28.508B | ||
| BIIB | BIOGEN INC | 11.44 | 27.573B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 26.65B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.41 | 25.108B | ||
| MRNA | MODERNA INC | N/A | 20.96B | ||
| INCY | INCYTE CORP | 12.23 | 19B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About SVRA
Company Profile
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
Company Info
IPO: 2001-06-25
SAVARA INC
1717 Langhorne Newtown Road, Suite 300
Langhorne PENNSYLVANIA 78746 US
CEO: Matthew Pauls
Employees: 70
Phone: 15126141848
SAVARA INC / SVRA FAQ
Can you describe the business of SAVARA INC?
Savara, Inc. is a clinical-stage pharmaceutical company, which engages in the development and commercialization of novel therapies for the treatment of serious or life-threatening rare respiratory diseases. The company is headquartered in Langhorne, Pennsylvania and currently employs 70 full-time employees. The company went IPO on 2001-06-25. The firm is focused on rare respiratory diseases. The Company’s lead program, molgramostim inhalation solution (MOLBREEVI or molgramostim), is an inhaled biologic, specifically an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase III development for autoimmune pulmonary alveolar proteinosis (aPAP). MOLBREEVI is an inhaled formulation of recombinant human GM-CSF and is being developed for the treatment of aPAP. MOLBREEVI is administered once daily by inhalation via a high efficiency nebulizer, the eFlow Nebulizer System (PARI Pharma GmbH). Pulmonary alveolar proteinosis (PAP) is a rare lung disease characterized by the accumulation of surfactant in the alveoli (or air sacs) of the lungs. The firm is engaged in the advancement of the MOLBREEVI aPAP program and the Phase III IMPALA-2 clinical trial and outsourcing capital-intensive operations.
What is the current price of SVRA stock?
The current stock price of SVRA is 5.12 USD. The price increased by 3.64% in the last trading session.
Does SAVARA INC pay dividends?
SVRA does not pay a dividend.
What is the ChartMill technical and fundamental rating of SVRA stock?
SVRA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for SAVARA INC?
SAVARA INC (SVRA) operates in the Health Care sector and the Biotechnology industry.